Lawmakers push Mylan, Teva Pharma over drug pricing probe

U.S. House Oversight Chairman Elijah Cummings, along with U.S. Senator Bernie Sanders, the ranking member on the Senate Budget Committee, sent the letters to Mylan NV, Teva Pharmaceutical Industries Ltd and privately held Heritage Pharmaceuticals, the lawmakers said in a statement.

WASHINGTON: The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Read Also: Biocon, Mylan launch biosimilar Ogivri for treatment of breast, stomach cancer in Australia

U.S. House Oversight Chairman Elijah Cummings, along with U.S. Senator Bernie Sanders, the ranking member on the Senate Budget Committee, sent the letters to Mylan NV, Teva Pharmaceutical Industries Ltd and privately held Heritage Pharmaceuticals, the lawmakers said in a statement.

Read Also: Pfizer generic unit Upjohn to merge with Mylan; new entity aims revenue of 19-20 billion Dollar for 2020